NO990560L - Kjemisk modifiserte polypeptider - Google Patents

Kjemisk modifiserte polypeptider

Info

Publication number
NO990560L
NO990560L NO990560A NO990560A NO990560L NO 990560 L NO990560 L NO 990560L NO 990560 A NO990560 A NO 990560A NO 990560 A NO990560 A NO 990560A NO 990560 L NO990560 L NO 990560L
Authority
NO
Norway
Prior art keywords
modified polypeptide
chemically modified
modified polypeptides
polypeptide
modified
Prior art date
Application number
NO990560A
Other languages
English (en)
Other versions
NO322978B1 (no
NO990560D0 (no
Inventor
Motoo Yamasaki
Toshiyuki Suzawa
Ken Kobayashi
Noboru Konishi
Shiro Akinaga
Kumiko Maruyama
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO990560D0 publication Critical patent/NO990560D0/no
Publication of NO990560L publication Critical patent/NO990560L/no
Publication of NO322978B1 publication Critical patent/NO322978B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19990560A 1997-06-06 1999-02-05 Kjemisk modifisert polypeptid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat. NO322978B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14934297 1997-06-06
PCT/JP1998/002504 WO1998055500A1 (en) 1997-06-06 1998-06-05 Chemically modified polypeptides

Publications (3)

Publication Number Publication Date
NO990560D0 NO990560D0 (no) 1999-02-05
NO990560L true NO990560L (no) 1999-03-26
NO322978B1 NO322978B1 (no) 2006-12-18

Family

ID=15473025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990560A NO322978B1 (no) 1997-06-06 1999-02-05 Kjemisk modifisert polypeptid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat.

Country Status (14)

Country Link
US (2) US6583267B2 (no)
EP (1) EP0921131B1 (no)
JP (1) JP4011124B2 (no)
KR (1) KR100565022B1 (no)
CN (1) CN1250566C (no)
AT (1) ATE469166T1 (no)
AU (1) AU744085B2 (no)
CA (1) CA2263795C (no)
DE (1) DE69841682D1 (no)
HU (1) HUP0001153A3 (no)
NO (1) NO322978B1 (no)
NZ (1) NZ334068A (no)
RO (1) RO121474B1 (no)
WO (1) WO1998055500A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
JP4011124B2 (ja) 1997-06-06 2007-11-21 協和醗酵工業株式会社 化学修飾ポリペプチド
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
KR100773323B1 (ko) 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
CA2467557A1 (en) * 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Agent which mobilizes multipotential stem cells from tissues to peripheral blood
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
JP5399906B2 (ja) 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CA3111576A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
MX2023005235A (es) * 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
JPH0644927B2 (ja) * 1987-03-14 1994-06-15 日本油脂株式会社 徐放性活性成分放出剤
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH0796558B2 (ja) * 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
JP2931622B2 (ja) * 1989-05-27 1999-08-09 住友製薬株式会社 ポリエチレングリコール誘導体を得る製造方法
JPH03236400A (ja) * 1990-02-09 1991-10-22 Kirin Brewery Co Ltd 化学修飾ポリペプチド及びその用途
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JPH06319537A (ja) 1993-05-18 1994-11-22 Daikin Ind Ltd 修飾ペプチドおよびその製造方法
JP4011106B2 (ja) * 1994-02-23 2007-11-21 協和醗酵工業株式会社 血小板増殖促進剤
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
JP4011124B2 (ja) 1997-06-06 2007-11-21 協和醗酵工業株式会社 化学修飾ポリペプチド
DE69939036D1 (de) * 1998-04-28 2008-08-14 Serono Lab PEG Konjugate von LHRH Analogen

Also Published As

Publication number Publication date
NO322978B1 (no) 2006-12-18
US7547675B2 (en) 2009-06-16
AU744085B2 (en) 2002-02-14
CN1236370A (zh) 1999-11-24
AU7551298A (en) 1998-12-21
HUP0001153A3 (en) 2000-12-28
KR100565022B1 (ko) 2006-03-30
NO990560D0 (no) 1999-02-05
HK1022919A1 (en) 2000-11-03
KR20000068069A (ko) 2000-11-25
CN1250566C (zh) 2006-04-12
US20020028912A1 (en) 2002-03-07
HUP0001153A2 (hu) 2000-10-28
NZ334068A (en) 2000-07-28
ATE469166T1 (de) 2010-06-15
JP4011124B2 (ja) 2007-11-21
EP0921131A1 (en) 1999-06-09
DE69841682D1 (de) 2010-07-08
CA2263795A1 (en) 1998-12-10
EP0921131A4 (en) 2002-11-27
RO121474B1 (ro) 2007-06-29
EP0921131B1 (en) 2010-05-26
US20030195339A1 (en) 2003-10-16
WO1998055500A1 (en) 1998-12-10
US6583267B2 (en) 2003-06-24
CA2263795C (en) 2008-02-19

Similar Documents

Publication Publication Date Title
NO990560L (no) Kjemisk modifiserte polypeptider
PT96068A (pt) Processo para a producao de proteina biologicamente activa
ES2063278T3 (es) Proteina morfogenetica de hueso.
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
PT792287E (pt) Analogos peptidicos da proteina basica da mielina humana
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
DE69006628D1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin.
FI960309L (fi) Neisseria meningitidis, B-ryhmän ulkomembraanin poriiniproteiinien korkean tason ilmentäminen, puhdistaminen ja uudelleenlaskostaminen
ATA293589A (de) Neue chinolinsulfonaminoderivate und verfahren zu deren herstellung sowie pharmazeutische zusammensetzung
ATE109793T1 (de) Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
ATE323766T1 (de) Glykosylierte leptinzusammensetzungen und zugehörige verfahren
FI961536A7 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa s amoin kuin siten saatu farmaseuttinen valmiste
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
DE69636714D1 (de) G-CSF TPO Fusionsproteine
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
FI920058A7 (fi) Menetelmä hirudiinien ja hirudiinin kaltaisten polypeptidien tuottamis eksi rekombinanttitekniikalla
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
DE69114707D1 (de) Neue alpha-glukosidaseinhibitoren.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
CA2247998A1 (en) Fragments of cr1 and their use
BR9612675A (pt) Polipeptídeo ou composicão de polipeptídeo composicão imunogenica adequada para admistracão por injecao e uso de polipeptideo ou de composicão imunogenica
WO1994015962A3 (en) Derivatized calcitonins

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees